伊沃内西马布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|July 29, 2024
概括
一种新的双特异性抗体Ivonescimab针对PD-1和VEGF-A. 它在中国首次获得批准,用于在TKI治疗后治疗晚期非小细胞肺癌 (NSCLC).
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 仍然是全球癌症死亡的主要原因.
- 针对免疫检查点 (PD-1/PD-L1) 和瘤血管生成 (VEGF-A/VEGFR2) 提供了一个有希望的治疗策略.
- 对氨酸激酶抑制剂 (TKI) 的耐药性需要EGFR突变NSCLC的新型治疗方法.
研究的目的:
- 总结一下ivonescimab的发展里程碑,这是一个针对PD-1和VEGF-A的双特异抗体.
- 为了突出中国首次对IVONESCIMAB在特定NSCLC患者群体的监管批准.
- 提供IVONESCIMAB的作用机制和临床发展的概述.
主要方法:
- 开发一流的,人性化的,四价双特异性单克隆抗体 (ivonescimab).
- 临床前和临床研究评估PD-1/PD-L1和VEGF-A/VEGFR2通路的双重阻断.
- 监管提交和审查过程导致市场批准.
主要成果:
- 伊沃内西马布同时阻断PD-1/PD-L1介导的免疫抑制和VEGF-A/VEGFR2介导的瘤血管生成.
- 在2024年5月,IVONESCIMAB在中国获得了首次批准.
- 该批准适用于EGFR突变局部晚期或转移性非状细胞核癌患者,这些患者在TKI治疗后进展,结合化疗.
结论:
- 伊沃内西马布代表了NSCLC治疗的重大进步,特别是在对TKI获得耐药性的患者中.
- 伊尼西马布的双重向机制为克服瘤免疫抑制和血管生成提供了一种新的方法.
- 目前正在进行的全球临床试验预计将进一步定义ivonescimab在各种固体瘤中的作用.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
相关概念视频
01:19Pharmacovigilance
805
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
805
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
01:02Prescription, Nonprescription and Orphan Drugs
711
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
711
01:29Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
01:26Drug Administration and Therapy Phases: Overview
426
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
426